Antihistamines Offer Little Eczema Relief, Review Finds

Key Takeaways

• Across randomized trials of mainly moderate to severe eczema, oral H1 antihistamines were associated with only small, clinically unimportant reductions in eczema and itch severity.
• Sleep disturbance and flare-ups were not clearly reduced with oral antihistamine add-on therapy in atopic dermatitis.
• First-generation sedating antihistamines probably increased cognitive impairment, including sedation and drowsiness, in randomized atopic dermatitis trials.
• Estimated common antihistamine use in eczema was about one in five UK patients and nearly half of US patients.

Persistent itch, sleep disruption, and recurrent flares keep oral antihistamines in regular use as add-on treatment for atopic dermatitis, even though their value for eczema symptom control remains uncertain. In eczema care, the unresolved question is whether these drugs meaningfully relieve the symptoms patients notice most or chiefly add adverse effects to background skin-directed therapy. Investigators therefore evaluated randomized evidence across patient-important outcomes in day-to-day eczema care.

Chu et al. in BMJreported a systematic review and network meta-analysis of randomized evidence in atopic dermatitis. The review included 47 randomized controlled trials involving 6,230 children and adults with mainly moderate to severe eczema.

Comparisons included oral H1 antihistamines, H2 blockers, mast cell stabilizers, and combinations of these agents versus placebo, with or without background moisturizers or steroid creams. Across trials, the median reported mean age was 20 years, and the median proportion of female participants was 52%. Outcomes included eczema severity, itch severity, sleep disturbance, flare-ups, quality of life, sedation or drowsiness, and treatment discontinuation.

Compared with placebo, oral H1 antihistamines likely produced small but clinically unimportant reductions in eczema severity and itch severity, according to the authors. Antihistamines may not have reduced sleep disturbance or flare-ups in a meaningful way. First-generation H1 antihistamines probably increased cognitive impairment and neurocognitive adverse effects, including sedation and drowsiness, and may also have increased discontinuation because of side effects.

The included trials were described as being of varying quality, and investigators assessed risk of bias and certainty of evidence using established tools. They also acknowledged limitations related to the nature of the included trials. In the authors’ interpretation, the overall pattern did not show meaningful improvement in patient-important outcomes and instead pointed to harms, especially with sedating agents.

Chu et al. concluded that the BMJ review of antihistamines for atopic dermatitis did not support routine oral antihistamine use for atopic dermatitis management. The authors further indicated that the findings may inform future guideline updates, but the main observed balance was limited symptom benefit alongside increased harms.

Clinician Questions

Which antihistamine classes were included in the atopic dermatitis evidence review?

The evidence base covered adjunctive oral H1 antihistamines, H2 blockers, mast cell stabilizers, and combinations of these agents, each compared with placebo given with or without background moisturizers or steroid creams in children and adults with mainly moderate to severe eczema.

What patient-important outcomes were assessed for oral antihistamines in atopic dermatitis trials?

The review evaluated eczema severity, itch severity, sleep disturbance, flare-ups, quality of life, sedation and drowsiness, and treatment discontinuation, clarifying that it measured both symptom control and tolerability.